megestrol

MA significantly improves nutritional status and ameliorates cancer-related fatigue, thereby enhancing the quality of life in patients with cancer cachexia. Our findings provide robust evidence supporting the multi-dimensional benefits of MA in cachexia management, extending beyond mere weight gain to include muscle mass preservation and patient-centered symptom relief.

P2, N=88, Not yet recruiting, Nanfang Hospital, Southern Medical University

Background: Oral progestogens, including megestrol acetate (MA) and medroxyprogesterone acetate (MPA), have largely been superseded by aromatase inhibitors, tamoxifen, and selective oestrogen receptor degraders (SERDs) in oestrogen receptor-positive (ER-positive) metastatic breast cancer. While prior exposure to CDK4/6 inhibitors was associated with shorter PFS, patients without liver metastases appeared to derive the greatest benefit. These findings support a role for oral progestogens in selected patients who have exhausted standard therapeutic options.

P=N/A, N=56, Recruiting, Shandong Cancer Hospital and Institute | Trial completion date: Jul 2027 --> Feb 2028 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jul 2027 --> Dec 2027

This case report describes a 41-year-old patient who, despite PR and PE negativity, responded to conservative management with hysteroscopic resection, a levonorgestrel-releasing intrauterine device, metformin, and later megestrol, achieving complete histological remission in 15 months. The evolving literature suggests that alternative strategies, such as immune modulation and aromatase inhibitors, may further expand options. Individualized management remains crucial, balancing oncological safety with reproductive goals through continuous reassessment and engagement with emerging therapeutic evidence.

P1, N=88, Recruiting, Second Xiangya Hospital of Central South University | Initiation date: Jan 2026 --> Apr 2026

P3, N=326, Recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University | Not yet recruiting --> Recruiting | Phase classification: P1 --> P3

P3, N=132, Not yet recruiting, Sun Yat-sen University

P3, N=227, Active, not recruiting, Alliance for Clinical Trials in Oncology | Recruiting --> Active, not recruiting | N=360 --> 227

P2, N=250, Recruiting, Merck Sharp & Dohme LLC

P=N/A, N=82, Not yet recruiting, Hospital Universitari de Bellvitge | Trial completion date: Dec 2026 --> Sep 2028 | Initiation date: May 2026 --> Sep 2026 | Trial primary completion date: Jun 2026 --> May 2027

P3, N=116, Not yet recruiting, Hunan Province Tumor Hospital